An X, Ouyang X, Zhang H, Li T, Huang Y-Y, Li Z, Zhou D*, Li Q-X. Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
J Vis Exp 2018; (140), e57460
*State Key Laboratory of Natural and Biomimetic Drugs, Peking University
Pancreatic ductal adenocarcinoma (PDAC) does not respond to a range of cancer therapies (e.g. chemo-, targeted, and immunotherapy), partially due to an abundant tumor microenvironment (TME), that protects tumor cells from treatment.
Novel preclinical models are needed to develop new anti-PDAC agents, as well as accurately recapitulate the TME of human pancreatic cancers. Orthotopically implanted tumor homograft models fit this need, and allow testing of a range of oncology and immuno-oncology regimens.
The tumor homograft models are derived from transplants of mouse spontaneous PDAC originating from genetically engineered KPC mice. This publication details model generation, and provides an in depth method for immunophenotyping the model TME.
Download This Publication To Understand:
- How model orthotopic implantation results in efficient tumor growth similar to subcutaneous models, but that different TME immune profiles are observed
- How to perform and optimize multi-color flow cytometry including complex marker panel design, compensation, and gating strategies
- That orthotopically implanted KPC tumor homograft models provide an ideal model for PDAC preclinical research